Nureca Limited has resubmitted its Investor Presentation for the quarter ended December 31, 2025 (Q3 FY26). The resubmission is to update the registered address of the company on page 26 of the presentation to “Andheri West B-205, Bldg -42, B wing, Dhanashree heights, Azad Nagar Sangam CHS, Andheri West, Mumbai - 400053“. All other details within the presentation remain unchanged.

The company's financial performance for Q3 FY26 showed a Year-on-Year (YoY) growth of 27% in Revenue from Operations, reaching ₹540 million (₹54 crore), compared to ₹425 million (₹42.5 crore) in Q3 FY25. EBITDA saw a significant YoY growth of 314%, rising to ₹54 million (₹5.4 crore) from ₹25.4 million (₹2.54 crore) in the prior year period. Profit After Tax (PAT) also demonstrated substantial growth, increasing by 233% YoY to ₹37 million (₹3.7 crore) from a loss of ₹28 million (₹-2.8 crore) in Q3 FY25.

For the nine-month period ended December 31, 2025 (9M FY26), Revenue from Operations stood at ₹1536 million (₹153.6 crore), while EBITDA was ₹130 million (₹13 crore) and PAT was ₹82 million (₹8.2 crore).

The presentation highlights Nureca's strategic pillars including D2C growth, Omnipresence, Manufacturing, and Connected Health. The company emphasizes its digital-first approach with over 90% revenue generated through online sales and a debt-free, asset-light business model. Key business highlights include a strong focus on product design, supply chain, distribution, and marketing, with over 285 active SKUs and a significant in-house product development team. Nureca also highlighted its manufacturing subsidiary, Nureca Technologies Pvt Limited, and its expansion of offline distribution networks.

The company's vision is to be a global leader in healthcare innovation, empowering individuals through technology and quality solutions. The mission focuses on providing world-class healthcare solutions that integrate advanced technology with personalized care.